

**LACHMAN CONSULTANT SERVICES, INC.**  
CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE, WESTBURY, NY 11590  
(516) 222-6222 • FAX (516) 683-1887

June 8, 2004

**OVERNIGHT COURIER 6/8/04**

Dockets Management Branch  
Food and Drug Administration (HFA-305)  
Department of Health and Human Services  
5630 Fishers Lane, Room 1061  
Rockville, MD 20852

**Correction of 1/29/04 Amendment to  
Docket 2003P-0159/CP1**

Dear Sir:

Please note that an inadvertent error appears in the January 29, 2004 amendment submitted referenced above. The reference-listed drug (RLD) in certain instances was referred to as a tablet and the proposed product referred to as a capsule. The RLD is a **capsule** and the proposed product is a **tablet**.

The enclosed letter corrects that error.

Respectfully submitted,



Robert W. Pollock  
Vice President  
Lachman Consultant Services, Inc  
1600 Stewart Avenue  
Westbury, NY 11590

RWP/pk

Attachment: Corrected Letter

cc: Emily Thakur

R03P4160a

2003P-0159

CR 1

**LACHMAN CONSULTANT SERVICES, INC.**  
CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE, WESTBURY, NY 11590  
(516) 222-6222 • FAX (516) 683-1887

June 8, 2004

**OVERNIGHT COURIER 6/8/04**

Dockets Management Branch  
Food and Drug Administration (HFA-305)  
Department of Health and Human Services  
5630 Fishers Lane, Room 1061  
Rockville, MD 20852

**CORRECTED VERSION**

**Of January 29, 2004 Submission  
Amendment to Citizen Petition  
Docket Number 2003P-0159/CP1  
Inclusion of Pediatric Waiver Request**

Dear Sir or Madam:

The petition cited above was submitted on April 14, 2003. The petition requested the Commissioner of the Food and Drug Administration to declare that the drug products, Venlafaxine Hydrochloride Extended-release Tablets, 37.5 mg (base), 75 mg (base) and 150 mg (base) are suitable for submission in an abbreviated new drug application (ANDA).

In December of 2003, Congress passed the Pediatric Research Equity Act of 2003 that amended the Federal Food Drug and Cosmetic Act to provide the Agency authority to require drug firms to study certain drugs in pediatric patients, if the Agency felt that such study would provide beneficial health data for that patient population. The act also provides a provision for a waiver from such requirement if:

- (iii) the drug or biological product;
- (I) does not represent a meaningful therapeutic benefit over existing therapies for pediatric patients; and
- (II) is not likely to be used in a substantial number of pediatric patients.

The petitioner hereby requests that a waiver from the conduct of pediatric patient be granted for the approval of this petition to permit subsequent ANDA filing.

The reference-listed drug product is currently available in an extended-release **capsule** and appears not to be recommended for use in pediatric patients. The proposed product is an extended-release **tablet**. Venlafaxine has undergone pediatric studies as evidenced by the award of pediatric exclusivity to the innovator product. In this regard, it is not known whether a

supplemental application for a labeling change has been submitted and if so whether it will be approved. However, since pediatric studies were conducted on this product, it would not seem reasonable to request that similar studies be repeated for a dosage form change thereby unnecessarily exposing children to the drug to prove what is already known. Should the innovator labeling change, the generic will be required to change its labeling to match the innovator unless the change is protected by patent or a period of market exclusivity. The ANDA applicant will be required to revise its labeling in accord with the regulations and the provisions of the Best Pharmaceuticals for Children Act. The introduction of a **tablet** dosage form of the product is not likely to provide a meaningful therapeutic benefit over existing therapies for pediatric patients nor would it be expected to diminish the knowledge gained by the conduct of pediatric studies already completed. For these reasons the change in dosage form from an extended-release **capsule** to an extended-release **tablet** would not likely result in use in the pediatric population. In addition, based on the labeling of the proposed product, it is not likely to be used in a substantial number of pediatric patients.

For the reasons stated above and consistent with the provisions of the Pediatric Research Equity Act of 2003, the petitioner respectfully requests that this waiver be granted.

Sincerely,



Robert W. Pollock *PK*  
Vice President  
Lachman Consultant Services, Inc.  
1600 Stewart Avenue  
Westbury, NY 11590

RWP/pk

cc: Emily Thomas (Office of Generic Drugs)

R03P4160

From Origin ID (516)683-1881  
 Westbury Office  
 LACHMAN CONSULTANT SERVICES  
 1600 STEWART AVE  
 SUITE 604  
 WESTBURY, NY 11590




Ship Date 08JUN04  
 Actual Wgt 1 LB  
 System# 1879030/INET1800  
 Account# S \*\*\*\*\*

REF Documents from LCS



Delivery Address Bar Code

SHIP TO (301)827-6860 **BILL SENDER**  
**Division of Dockets Management**  
**Food and Drug Administration**  
**Dept. of Health & Human Services**  
**5630 Fishers Lane, Room 1061**  
**Rockville, MD 20852**



**STANDARD OVERNIGHT**

**WED**

TRK# 7926 5800 1010


FORM 0201

Deliver By 09JUN04

IAD A2

20852 -MD-US

**ZM GAIA**



Shipping Label: Your shipment is complete

1. Use the 'Print' feature from your browser to send this page to your laser or inkjet printer.
2. Fold the printed page along the horizontal line
3. Place label in shipping pouch and affix it to your shipment so that the barcode portion of the label can be read and scanned.

**Warning: Use only the printed original label for shipping. Using a photocopy of this label for shipping purposes is fraudulent and could result in additional billing charges, along with the cancellation of your FedEx account number.**

Use of this system constitutes your agreement to the service conditions in the current FedEx Service Guide, available on fedex.com. FedEx will not be responsible for any claim in excess of \$100 per package, whether the result of loss, damage, delay, non-delivery, misdelivery, or misinformation, unless you declare a higher value, pay an additional charge, document your actual loss and file a timely claim. Limitations found in the current FedEx Service Guide apply. Your right to recover from FedEx for any loss, including intrinsic value of the package, loss of sales, income interest, profit, attorney's fees, costs, and other forms of damage whether direct, incidental, consequential, or special is limited to the greater of \$100 or the authorized declared value. Recovery cannot exceed actual documented loss. Maximum for items of extraordinary value is \$500, e.g. jewelry, precious metals, negotiable instruments and other items listed in our Service Guide. Written claims must be filed within strict time limits, see current FedEx Service Guide.